摘要 |
<p>Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 represents an alkylsulfonylamino group or the like; R2 and R3 (a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R4)- or -CH(R4)-; R4 represents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.</p> |
申请人 |
MITSUBISHI TANABE PHARMA CORPORATION |
发明人 |
KAWAGUCHI, TAKAYUKI;AKATSUKA, HIDENORI;AWAI, NOBUMASA;TAKAHASHI, YOICHI;IIJIMA, TORU |